Kintara Therapeutics, Inc.

NASDAQ (USD): Kintara Therapeutics, Inc. (KTRA)

Last Price

0.154

Today's Change

+0.009 (6.20%)

Day's Change

0.146 - 0.159

Trading Volume

3,250,969

Overview

Market Cap

8 Million

Shares Outstanding

55 Million

Avg Volume

14,853,404

Avg Price (50 Days)

0.11

Avg Price (200 Days)

1.54

PE Ratio

-0.03

EPS

-5.22

Earnings Announcement

09-May-2024

Previous Close

0.14

Open

0.15

Day's Range

0.146 - 0.1588

Year Range

0.081 - 5.6

Trading Volume

3,250,969

Price Change Highlight

1 Day Change

6.00%

5 Day Change

4.42%

1 Month Change

18.14%

3 Month Change

34.35%

6 Month Change

-64.26%

Ytd Change

-3.27%

1 Year Change

-95.20%

3 Year Change

-99.77%

5 Year Change

-99.92%

10 Year Change

-99.97%

Max Change

-99.98%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment